• Discover Astex
    • Our Mission & Values
    • Our Leadership Team
    • Our History
    • Corporate Social Responsibility
  • R&D
    • Clinical Pipeline
      • Partnered Products and Programs
        • Kisqali® (ribociclib) CDK4/6 inhibitor (Oncology)
        • Balversa® (erdafitinib) FGFr inhibitor (Oncology)
        • Truqap® PKB/Akt Inhibitor (Oncology)
        • KRAS Oncogene (Oncology)
        • Beroterkib (ASTX029) Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)
        • ASTX295 Oral Murine Double Minute 2 (MDM2) antagonist (Solid Tumors)
        • SHP2 (Oncology)
        • P53 tumour suppressor protein (Oncology)
      • Proprietary Products and Programs
        • Tolinapant (ASTX660) Dual IAP Antagonist (T-cell Lymphomas)
    • Pyramid™ Discovery Platform
    • Oncology and CNS Discovery
    • Sustaining Innovation Postdocs
  • Partnering
  • Our People & Culture
    • Career Opportunities
  • Media
    • Press Releases
    • Conferences & Meetings
    • Presentations & Publications
    • Interactive Scientific Resources
      • Interactive Software
    • Astex in the News
  • Contact
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
You are here: Home1 / 20092 / Astex reports positive data from its Phase I study of AT9283 at the ASCO...

Astex reports positive data from its Phase I study of AT9283 at the ASCO Annual Meeting 2009

16 May 2009/in 2009, News

Astex reports positive data from its Phase I study of AT9283 at the ASCO Annual Meeting 2009

https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg 0 0 webadmin https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg webadmin2009-05-16 12:39:392016-11-28 12:40:02Astex reports positive data from its Phase I study of AT9283 at the ASCO Annual Meeting 2009

© Astex Pharmaceuticals
All rights reserved

astex

Useful links

  • Home
  • Sitemap
  • Privacy Policy
  • Terms of Use
  • Legal
  • LinkedIn

Member of the Otsuka Group

A selection of photos on this website
is courtesy of Valerio Berdini

Link to: SuperGen’s MP-470 Demonstrates Clinical Benefit in Lung Cancer Patients Link to: SuperGen’s MP-470 Demonstrates Clinical Benefit in Lung Cancer Patients SuperGen’s MP-470 Demonstrates Clinical Benefit in Lung Cancer Patien... Link to: SuperGen Names Mohammad Azab, M.D., Chief Medical Officer Link to: SuperGen Names Mohammad Azab, M.D., Chief Medical Officer SuperGen Names Mohammad Azab, M.D., Chief Medical Officer
Scroll to top Scroll to top Scroll to top
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok